Cargando…

31 Emergency Department-Based Monoclonal Antibody Therapy for Patients With Mild to Moderate COVID-19

Detalles Bibliográficos
Autores principales:	Lim, C., Eiting, E., O'Neill, A., Farraj, R., Koshy, S., Simms, C., Devlin, A., Nunez, J., Calderon, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Mosby, Inc. 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335421/ http://dx.doi.org/10.1016/j.annemergmed.2021.07.032

Ejemplares similares

Emergency Department-based monoclonal antibody therapy for patients with mild to moderate COVID-19
por: Devlin, Amanda, et al.
Publicado: (2023)

Development of a combined paediatric emergency department and observation unit
por: Lim, Czer Anthoney Enriquez, et al.
Publicado: (2020)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
por: Arimura, Ken, et al.
Publicado: (2023)

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
por: Marwah, Vikas, et al.
Publicado: (2023)

Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
por: Franchin, Giovanni, et al.
Publicado: (2021)

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
por: Thilagar, Bright P., et al.
Publicado: (2022)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
por: Amanam, Idoroenyi, et al.
Publicado: (2021)

Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease
por: Hao, Ying, et al.
Publicado: (2023)

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience
por: Amanam, Idoroenyi, et al.
Publicado: (2023)

Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies
por: Li, Jinfeng, et al.
Publicado: (2017)

Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies
por: Jary, Aude, et al.
Publicado: (2022)

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19
por: Bierle, Dennis M., et al.
Publicado: (2021)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo
Publicado: (1994)

More Accessible COVID-19 Treatment Through Monoclonal Antibody Infusion in the Emergency Department
por: Heinert, Sara W., et al.
Publicado: (2022)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021)

The monoclonal antibody HCM31 specifically recognises the Sd(a) tetrasaccharide in goblet cell mucin
por: Tsubokawa, Daigo, et al.
Publicado: (2012)

Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study
por: Bronton, Kevin, et al.
Publicado: (2021)

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
por: Huizinga, T. W. J., et al.
Publicado: (2017)

Monoclonal antibodies for imaging and therapy.
por: Epenetos, A. A., et al.
Publicado: (1989)

Mild-to-Moderate Croup Presentations in Patients With COVID-19 Infection
por: Mathew, Danica, et al.
Publicado: (2022)

Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
por: Moreira, Thais G., et al.
Publicado: (2021)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
por: Moreira, Thais G., et al.
Publicado: (2022)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Molecular Characterization of Two Monoclonal Antibodies against the Same Epitope on B-Cell Receptor Associated Protein 31
por: Kim, Won-Tae, et al.
Publicado: (2016)

Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
por: Desoubeaux, Guillaume, et al.
Publicado: (2016)

Monoclonal Antibodies in Cancer
por: Ghosh, A.K.
Publicado: (1986)

34 A Remote Monitoring Program for Patients Discharged from the Emergency Department With Mild to Moderate COVID-19 Infection
por: Voge, V., et al.
Publicado: (2022)

Decay of Fc-dependent antibody functions after mild to moderate COVID-19
por: Lee, Wen Shi, et al.
Publicado: (2021)

Antimicrobial prescribing in patients admitted through the emergency department of connolly hospital
por: Messmer, Lauren, et al.
Publicado: (2015)

Virtual triaging in an eye emergency department during the COVID-19 pandemic
por: Hurley, Daire J., et al.
Publicado: (2022)

A Monoclonal–Monoclonal Antibody Based Capture ELISA for Abrin
por: Tam, Christina C., et al.
Publicado: (2017)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study
por: Savoldi, Alessia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58fsdaobeciat018q1bqkjccoc